Wall Street – Page 9

Merck’s Keytruda extends survival in lung cancer study

Accelerated Drug Approvals, Chemotherapy, Clinical Trials, FDA, FDA/Regulatory, Forecasts, Health, Immune System, Immune Systems, Immunotherapies, Immunotherapy, Lung Cancer, Non-Small Cell Lung Cancer, PD-1/PD-L1 inhibitors, R&D, Studies, Tumors, Wall Street

Merck & Co’s approved Keytruda lung cancer treatment provided superior overall survival to chemotherapy in a late-stage study of patients with advanced disease whose tumors produce a protein called PD-L1 […]

October 26, 2015/by Reuters Health

Lilly pill trumps Humira in arthritis study

Analysts, Forecasts, Forecasts, Health, Partnership, Partnerships, Potential Blockbusters, R&D, Rheumatoid Arthritis, Sales, Shares, Shares, Studies, Therapeutics, Wall Street

Eli Lilly and Co’s experimental pill for rheumatoid arthritis proved superior to Abbvie Inc’s leading injectable Humira treatment in a large study, which analysts said could prod them to raise […]

October 14, 2015/by Reuters Health

The odds that Merck & Co’s high-stakes cholesterol drug will succeed have dropped dramatically after Eli Lilly and Co said its similar medicine failed to reduce heart attacks and strokes, […]

October 12, 2015/by Reuters Health

Express Scripts sees $750 million in spending on new cholesterol drugs

Analysts, Approvals, Cholesterol, FDA/Regulatory, Generics, Health, Health Plans, Heart Attack, Heart Attacks, PCSK9 inhibitors, Pricing, R&D, Statins, Stroke, Studies, Therapeutics, Wall Street

Express Scripts Holding Co, the largest manager of prescription drug plans for U.S. employers and health plans, said it has reached deals to cover two costly new cholesterol drugs and […]

October 6, 2015/by Reuters Health

FDA expands approval of Merck’s Keytruda to lung cancer

Analysts, Approvals, FDA/Regulatory, Forecasts, Health, Health Insurer, Health Insurers, Immunotherapies, Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), PD-1/PD-L1 inhibitors, Pricing, Therapeutics, Wall Street

The U.S. Food and Drug Administration on Friday approved Merck & Co Inc’s immunotherapy, Keytruda, for patients with the most common form of lung cancer whose tumors produce a specific […]

October 2, 2015/by Reuters Health

Bristol pairs Yervoy safely with Opdivo vs lung cancer

Forecasts, Health, Immune System, Immunotherapy, Melanoma, Oncology, PD-1/PD-L1 inhibitors, R&D, Studies, Therapeutics, Wall Street

An early-stage study shows Bristol-Myers Squibb Co’s Opdivo treatment can be safely and effectively paired with relatively low and infrequent dosages of the company’s other immunotherapy, Yervoy, for patients with […]

September 7, 2015/by Reuters Health

Healthcare deals lift July to 7th busiest M&A month on record

Business, Deals, Generics, Health, Healthcare, M&A, Wall Street

A surge of takeover activity involving healthcare, financial and retail companies lifted the value of deals in July over $430 billion, making it the seventh-busiest mergers and acquisition month on […]

July 31, 2015/by Reuters Health

Amgen Raises 2015 Outlook, Results Beat Expectations

Analysts, Approvals, Biotech, Business, FDA/Regulatory, Forecasts, Health, PCSK9 inhibitors, People on the Move, Pricing, Quarterly results, R&D, Therapeutics, Wall Street

Amgen Inc. raised its 2015 guidance after reporting that its second-quarter earnings rose 6.9% on better-than-expected sales growth and lower operating expenses. For the year, the biotechnology company now expects […]

July 30, 2015/by Wall Street Journal Health

Gilead Sales Soar on Hepatitis Drugs

Analysts, Business, Health, Quarterly results, Shares, Stocks, Therapeutics, Wall Street

Gilead Sciences Inc. said its two key hepatitis C drugs, Sovaldi and Harvoni, generated about $4.9 billion in sales in the second quarter, topping Wall Street estimates, thanks to better-than-expected […]

July 29, 2015/by Wall Street Journal Health

Pfizer’s revenue, profit beat as vaccine sales rise

Analysts, Business, Health, Launches, Quarterly results, Therapeutics, Vaccines, Wall Street

Pfizer Inc on Tuesday reported better-than-expected second-quarter profit and revenue, helped by strong demand for its pneumonia vaccine and new breast cancer drug, sending its shares up 1 percent. The […]

July 28, 2015/by Reuters Health